218 related articles for article (PubMed ID: 18405182)
41. Denileukin diftitox: a concise clinical review.
Eklund JW; Kuzel TM
Expert Rev Anticancer Ther; 2005 Feb; 5(1):33-8. PubMed ID: 15757436
[TBL] [Abstract][Full Text] [Related]
42. Clinical experience with denileukin diftitox (ONTAK).
Foss F
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S11-6. PubMed ID: 16516670
[TBL] [Abstract][Full Text] [Related]
43. Denileukin diftitox as novel targeted therapy in non-Hodgkin's lymphoma.
Walker PL; Dang NH
Clin J Oncol Nurs; 2004 Apr; 8(2):169-74. PubMed ID: 15108419
[TBL] [Abstract][Full Text] [Related]
44. Treatment of systemic mastocytosis with denileukin diftitox.
Quintás-Cardama A; Kantarjian H; Verstovsek S
Am J Hematol; 2007 Dec; 82(12):1124. PubMed ID: 17665501
[No Abstract] [Full Text] [Related]
45. [Interferon-alpha and PUVA therapy for mycosis fungoides].
Marschalkó M; Kovács J; Somlai B; Berecz M; Hídvégi B; Hársing J; Désaknai M; Horváth A
Orv Hetil; 2001 Sep; 142(37):2021-3. PubMed ID: 11582733
[TBL] [Abstract][Full Text] [Related]
46. Denileukin diftitox: a novel immunotoxin.
Manoukian G; Hagemeister F
Expert Opin Biol Ther; 2009 Nov; 9(11):1445-51. PubMed ID: 19817678
[TBL] [Abstract][Full Text] [Related]
47. Bexarotene plus PUVA plus radiation combination therapy for mycosis fungoides.
Coors E
Dermatol Clin; 2008 Jan; 26 Suppl 1():33-5. PubMed ID: 18405185
[No Abstract] [Full Text] [Related]
48. Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies.
Duvic M
Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):33-40. PubMed ID: 17474358
[TBL] [Abstract][Full Text] [Related]
49. Confirmation of the activity of the interleukin-2 fusion toxin denileukin diftitox against chemorefractory chronic lymphocytic leukemia, including cases with chromosome 17p deletions and without detectable CD25 expression.
Morgan SJ; Seymour JF; Prince HM; Westerman DA; Wolf MM
Clin Cancer Res; 2004 May; 10(10):3572-5. PubMed ID: 15161717
[No Abstract] [Full Text] [Related]
50. Effective treatment of a case of refractory mycosis fungoides with imatinib.
Oka S; Yokote T; Hara S; Akioka T; Kobayashi K; Hirata Y; Yamano T; Endo Y; Tsuji M; Hanafusa T
Br J Haematol; 2006 May; 133(4):353. PubMed ID: 16643439
[No Abstract] [Full Text] [Related]
51. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia.
Frankel AE; Fleming DR; Hall PD; Powell BL; Black JH; Leftwich C; Gartenhaus R
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3555-61. PubMed ID: 14506141
[TBL] [Abstract][Full Text] [Related]
52. Treatment of cutaneous T-cell lymphoma/mycosis fungoides.
Parker SR; Bradley B
Dermatol Nurs; 2006 Dec; 18(6):566-70, 573-5. PubMed ID: 17286158
[TBL] [Abstract][Full Text] [Related]
53. Autologous graft-versus-host disease after denileukin diftitox and autologous stem cell transplantation for refractory T-cell lymphoma.
Zalom M; Lill M; Lukic D; Balzer BL; Lim S
Leuk Lymphoma; 2009 Jan; 50(1):124-6. PubMed ID: 19117212
[No Abstract] [Full Text] [Related]
54. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
Bouwhuis SA; Davis MD; el-Azhary RA; McEvoy MT; Gibson LE; Knudsen JM; Kist JM; Pittelkow MR
J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617
[TBL] [Abstract][Full Text] [Related]
55. Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia.
Frankel AE; Surendranathan A; Black JH; White A; Ganjoo K; Cripe LD
Cancer; 2006 May; 106(10):2158-64. PubMed ID: 16586495
[TBL] [Abstract][Full Text] [Related]
56. Adverse effects of denileukin diftitox and their management in patients with cutaneous T-cell lymphoma.
McCann S; Akilov OE; Geskin L
Clin J Oncol Nurs; 2012 Oct; 16(5):E164-72. PubMed ID: 23022942
[TBL] [Abstract][Full Text] [Related]
57. Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders.
Turturro F
Expert Rev Anticancer Ther; 2007 Jan; 7(1):11-7. PubMed ID: 17187516
[TBL] [Abstract][Full Text] [Related]
58. Bexarotene salvage therapy in a patient with refractory erythrodermic mycosis fungoides after failure on interferon/PUVA and methotrexate.
Dalle S; Thomas L
Dermatol Clin; 2008 Jan; 26 Suppl 1():39-41. PubMed ID: 18405186
[No Abstract] [Full Text] [Related]
59. DAB(389)IL-2 (denileukin diftitox, ONTAK): review of clinical trials to date.
Kuzel TM
Clin Lymphoma; 2000 Nov; 1 Suppl 1():S33-6. PubMed ID: 11707861
[TBL] [Abstract][Full Text] [Related]
60. Optimizing denileukin diftitox (Ontak) therapy.
Duvic M; Talpur R
Future Oncol; 2008 Aug; 4(4):457-69. PubMed ID: 18684057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
